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NG2 antigen is involved in leukemia invasiveness and central
nervous system inﬁltration in MLL-rearranged infant B-ALL
C Prieto1, B López-Millán1,16, H Roca-Ho1,16, RW Stam2,3, D Romero-Moya1, FJ Rodríguez-Baena4, A Sanjuan-Pla1, V Ayllón4, M Ramírez5,
M Bardini6, P De Lorenzo7, MG Valsecchi7, M Stanulla8, M Iglesias9, P Ballerini10, ÁM Carcaboso11, J Mora11, F Locatelli12, A Bertaina12,
L Padilla13, J Carlos Rodríguez-Manzaneque4, C Bueno1,14 and P Menéndez1,14,15
Mixed-lineage leukemia (MLL)-rearranged (MLLr) infant B-cell acute lymphoblastic leukemia (iMLLr-B-ALL) has a dismal prognosis
and is associated with a pro-B/mixed phenotype, therapy refractoriness and frequent central nervous system (CNS) disease/relapse.
Neuron-glial antigen 2 (NG2) is speciﬁcally expressed in MLLr leukemias and is used in leukemia immunophenotyping because of
its predictive value for MLLr acute leukemias. NG2 is involved in melanoma metastasis and brain development; however, its role in
MLL-mediated leukemogenesis remains elusive. Here we evaluated whether NG2 distinguishes leukemia-initiating/propagating
cells (L-ICs) and/or CNS-inﬁltrating cells (CNS-ICs) in iMLLr-B-ALL. Clinical data from the Interfant cohort of iMLLr-B-ALL
demonstrated that high NG2 expression associates with lower event-free survival, higher number of circulating blasts and more
frequent CNS disease/relapse. Serial xenotransplantation of primary MLL-AF4+ leukemias indicated that NG2 is a malleable marker
that does not enrich for L-IC or CNS-IC in iMLLr-B-All. However, NG2 expression was highly upregulated in blasts inﬁltrating
extramedullar hematopoietic sites and CNS, and speciﬁc blockage of NG2 resulted in almost complete loss of engraftment. Indeed,
gene expression proﬁling of primary blasts and primografts revealed a migratory signature of NG2+ blasts. This study provides new
insights on the biology of NG2 in iMLLr-B-ALL and suggests NG2 as a potential therapeutic target to reduce the risk of CNS disease/
relapse and to provide safer CNS-directed therapies for iMLLr-B-ALL.
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INTRODUCTION
B-cell acute lymphoblastic leukemia (B-ALL) is the most frequent
childhood cancer.1 Although better understanding of the disease
biology has increased the cure rate of pediatric B-ALL to480%,2,3
age o1 year (infants) and mixed-lineage leukemia (MLL, also
known as KMT2A) gene rearrangements (MLLr) remain two major
adverse prognostic factors in pediatric B-ALL.4 Of special interest is
the infant B-ALL carrying MLLr (iMLLr-B-ALL), particularly the
t(4;11)/MLL-AF4 (MA4, AF4 is also known as AFF1), which
possesses unique clinico-biological features and represents a
subtype of B-ALL with dismal prognosis.4–6 iMLLr-B-ALL has a
distinctive pro-B/mixed phenotype (CD10− with expression of
myeloid markers) and frequently shows therapy refractoriness and
central nervous system (CNS) inﬁltration.7
Treatment strategies aimed at targeting leukemia-initiating/
propagating cells (L-IC) and CNS-inﬁltrating leukemia cells (CNS-IC)
are necessary to overcome therapy resistance, relapse and CNS
disease.8,9 However, information on the nature of L-IC and CNS-IC
in iMLLr-B-ALL is scarce.4,10 The hierarchical stem cell model for
B-ALL has been challenged by the demonstration that
phenotypically diverse blasts both from MLL-germline and MLLr
B-ALL can reproduce the disease in immunodeﬁcient mice.8,9,11,12
Moreover, it has recently been reported that the ability to cross
the blood–cerebrospinal ﬂuid barrier is a generic property of all
B-ALL blasts.13 Whether CNS disease/relapse in t(4;11)/MA4 infant
B-ALL is driven by some leukemic cells speciﬁcally endowed with
the ability to enter and seed the CNS (CNS-ICs) or whether it is a
stochastic process in which all blasts have the same ability to enter
the CNS remains unknown.
Neuron-glial antigen 2 (NG2, also known as CSPG4) is a
transmembrane proteoglycan barely expressed in normal hema-
topoietic cells.14,15 By contrast, ~ 90% of 11q23/MLLr leukemias
speciﬁcally express NG2, which has been incorporated into
diagnostic workﬂows for leukemia immunophenotyping because
of its predictive value for MLLr.16–20 Interestingly, NG2 was
originally found highly expressed in melanoma21,22 and associated
with tumor cell migration and metastasis.23–25 In addition, NG2
has important role in the developing brain and is expressed by
oligodendrocyte progenitors.26,27 Nonetheless, its physiological
role in normal hematopoiesis and MLL-mediated leukemogenesis
remains unknown.14,15
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We have previously suggested that NG2 expression may be
dependent on the cell of origin where a speciﬁc MLL fusion
initially occurs.14 This, together with the reported role of NG2 in
the developing brain and in tumor cell migration/metastasis,
prompted us to hypothesize that NG2 expression in iMLLr-B-ALL
may contribute to the CNS disease/relapse frequently observed in
B-ALL. Clinical data from the Interfant cohort of iMLLr-B-ALLs
showed that high NG2 expression associates with lower event-free
survival (EFS), higher numbers of circulating blasts and more
frequent CNS disease/relapse. Serial xenotransplantation of
primary leukemias indicated that NG2 is a malleable marker that
does not enrich for L-IC or CNS-IC; however, its expression was
upregulated in MA4+ blasts inﬁltrating extramedullar hemato-
poietic sites and CNS, which was conﬁrmed by in vivo loss-of-
function assays and by a migratory transcriptomic signature of
NG2+ MLLr blasts. Our ﬁndings provide new insights on the
biology of NG2 in iMLLr B-ALL and encourages further studies to
address whether targeting NG2 offers a therapeutic window for
CNS disease/relapse.
MATERIALS AND METHODS
Patient samples and clinical data
Clinical data was available for 67 diagnostic iMLLr-B-ALLs. Fifty-ﬁve of these
infants were enrolled in the Interfant treatment protocol.28 Clinico-
biological correlations in Figure 1 are based on the Interfant cohort
except CNS disease data, which was obtained from 12 iMLLr-B-ALL used for
xenotransplantation studies. Table 1 shows the clinico-biological data of
the patients contributing samples for the experiments. The Institutional
Review Board of the Hospital Clinic of Barcelona approved the study, and
all patients’ parents gave written informed consent. Mononuclear cells
from patients with 485% of blasts were isolated from diagnostic bone
marrow (BM) or peripheral blood (PB) by density gradient centrifugation
using Ficoll-Hypaque. Blasts were FACS (ﬂuorescence-activated cell sorter)-
immunophenotyped using the monoclonal antibodies CD45-FITC, CD19-
APC, CD10-PerCP-Cy5.5, CD34-PE-Cy7 (BD Biosciences, San Jose, CA, USA)
and NG2-PE (Beckman, Barcelona, Spain), and NG2+ and NG2− blast
populations were FACS-sorted (FACS Aria, San Jose, CA, USA) (Figure 2a).
Mice transplantation and follow-up
Eight-to-14-week-old non-obese diabetic/LtSz-scid IL-2Rγ− /− mice (NSG;
n= 305 with male and female equally distributed) housed under pathogen-
free conditions were used. All experimental procedures were approved by
the Animal Care Committee of The Barcelona Biomedical Research Park
(DAAM7393). Limiting dilution doses (200k, 50k, 20k, 10k, 5k and 1k) of
sorted NG2+ and NG2− leukemic blasts were intra-BM (IBM)-transplanted
into sublethally irradiated mice as previously described.29–31 PB was
collected weekly to analyze leukemia engraftment by ﬂow cytometry. Mice
were killed when (i) disease symptoms were evident, (ii) leukemia
engraftment reached 10% in PB, or (iii) 140 days after transplantation.
For secondary transplantation, BM-derived mononuclear cells were
collected from primografts and IBM-transplanted (200k and 10k doses)
into irradiated secondary recipients (n= 47) as above. For intravenous (IV)
transplantation (n= 15), 200k and 50k NG2+ or NG2− sorted blasts were
transplanted via the lateral tail vein as described.32 IV-transplanted mice
were killed and analyzed when human chimerism was detectable in PB.
Figure 1. Clinical impact of NG2 expression in MLLr infant B-ALL. (a) The HR of relapse for different cutoffs of NG2 expression was investigated
to deﬁne NG2high versus NG2low patients (n= 55). The HR of 1.75 corresponding to the 40% cutoff was used. (b) Five-year EFS in NG2high and
NG2low patients (n= 55). (c) Frequency of patients with immature CD10neg immunophenotype in NG2high and NG2low subgroups (left panel),
WBC count at diagnostic (middle panel) and frequency of CNS disease (right panel) in NG2high and NG2low patients (n= 55).
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NG2 blocking experiments
In order to conﬁrm the role of NG2 in extramedullary inﬁltration, NG2+
primary blasts (200 000 per mouse) were incubated overnight with (i)
Chondroitinase (Chase) ABC, proteoglycan-degrading enzyme33,34 (0.1 U/
ml, Sigma, Madrid, Spain) or two different anti-NG2 monoclonal antibodies
(MoAb), (ii) the clone 7.1 (0.7 mg/ml, 7.1 MoAb-producing hybridoma
kindly provided by Professor Irwin Bernstein, Fred Hutchinson Cancer
Centre, Seattle, WA, USA) or (iii) the clone 9.2.21 (100 μg/ml), Abcam,
Cambridge, UK). NG2-blocked leukemic blasts were IV-transplanted into
irradiated NSG mice (n=29 mice) and leukemia engraftment analyzed
6 weeks later.
Analysis of leukemia engraftment and PB hematological counts
BM from injected tibia (IT), contralateral tibia (CL), liver, spleen and PB were
collected and analyzed at killing. Cells were stained with HLA-ABC-FITC and
CD45-APC-Cy7 antibodies to identify human leukemia by ﬂow cytometry.
Leukemia was immunophenotyped using CD19-V450, CD10-PerCP-Cy5.5,
CD34-PE-Cy7, CD33-APC and NG2-PE antibodies. Absolute white blood cell
counts (WBC) and differential counts were determined in PB.35 Hepatos-
plenomegaly was analyzed as described.36 The t(4;11)/MA4 rearrangement
was conﬁrmed by dual-fusion ﬂuorescence in situ hybridization in both
diagnostic NG2+ and NG2− cell populations and in engrafted leukemic cells
as described.37,38 Additionally, the cell cycle distribution of NG2+ and NG2−
leukemic blast was carried out by FACS (n=2) using propidium iodide as
described.35,39
Analysis of CNS inﬁltration
Mice skulls were retrieved at killing, ﬁxed, decalciﬁed, embedded in
parafﬁn and cut-stained with hematoxylin and eosin as previously
described.36 Ten skull sections/mouse (n= 60 mice) were analyzed and
classiﬁed by the presence/absence of inﬁltrating blasts. Human chimerism
in the skull was assessed by immunohistochemistry using the Benchmark
automated staining instrument and the human antibodies CD19 and CD45
(Roche, Madrid, Spain).
NG2 expression in CNS-ICs was analyzed by immunoﬂuorescence in skull
sections, using spleen as a positive control. Primary antibodies used were
rabbit anti-NG2 and rat anti-endomucin (Millipore, Madrid, Spain).
Secondary antibodies used were donkey anti-rabbit and anti-rat (Life
Technologies, Madrid, Spain). Human NG2 expression was conﬁrmed by
quantitative reverse transcriptase-PCR (qRT-PCR) in BM and extramedullar
tissues. RNA from the BM, liver and spinal cord of engrafted mice was
cDNA-converted and used for RT-PCR as previously described36 using
the following primers: NG2; Fwd-5′-CCTCTGGAAGAACAAAGGTCTC-3′,
Rev-5′-GAACTGTGTGACCTGGAAGAG-3′; and GAPDH (glyceraldehyde
3-phosphate dehydrogenase), Fwd-5′-GGGAAGCTTGTCATCAATGGA-3′,
Rev-5′-CGCCCCACTTGATTTTGG-3′. PCR conditions were 95 °C (20 s) fol-
lowed by 40 cycles of 95 °C (1 s) and 60 °C (20 s).
Microarray gene expression proﬁling
CD34+CD19+CD10−NG2+ and CD34+CD19+CD10− NG2− blast populations
were FACS-puriﬁed from the BM of three iMLLr-B-ALL for global gene
expression proﬁling (GEP) as described.40 Hierarchical clustering of genes
was performed with the one-minus-correlation metric and the unweighted
average distance. Gene functions and canonical pathways was analyzed
using the Ingenuity Pathway Analysis (IPA) software. Microarray data were
deposited in the public Gene Expression Omnibus database, accession
number GSE19475.
To conﬁrm gene expression changes, a qPCR array was used to analyze
the expression of 84 genes involved in epithelial-to-mesenchymal
transition/migration pathways (QIAGEN, Madrid, Spain). We speciﬁcally
compared circulating NG2+ and NG2− blasts recovered from primografts
transplanted with NG2+ versus NG2− cells. PCR Array was performed on a
Stratagene-Mx3000P System (San Diego, CA, USA) following the manu-
facturer’s instructions. Raw data were analyzed using the SABiosciences
(Madrid, Spain) web-based tool. Genes showing 41.5-fold-change
expression were considered differentially expressed between both groups.
IPA software was used to predict top regulated pathways/gene functions.41
Statistical analysis
Data are expressed as mean± s.e. of independent experiments unless
otherwise speciﬁed. Statistical comparisons were performed using either
paired or unpaired Student’s t-test, as appropriate. Fisher’s exact test was
used to assess the association between clinical characteristics and NG2
expression (high versus low levels). Statistical signiﬁcance was deﬁned as
P-valueo0.05. EFS was calculated as the time from diagnosis to ﬁrst failure
(induction failure, relapse, death or second neoplasm). EFS curves of
patients and xenografts were estimated according to Kaplan–Meier and
compared with the log-rank test. The Cox model was used to estimate the
impact of NG2 expression on the cause-speciﬁc hazard-of-relapse. Analyses
were performed with the SPSS Software (Hong Kong, China). L-IC
frequency was calculated using the ELDA software (http://bioinf.wehi.
edu.au/software/elda/) based on limiting dilution transplantation assays.42
RESULTS
High levels of NG2 are associated with a more immature/
aggressive phenotype in iMLLr-B-ALL
The clinical impact of NG2 expression was analyzed in an Interfant
cohort (n= 55) with the exception of CNS disease data that was
analyzed in the cohort (n= 12) of iMLLr-B-ALL (mainly MA4)
available for xenotransplantation (Table 1). Percentages of NG2
expression in the blast population (5–90%) were explored as
potential thresholds for the deﬁnition of high (NG2high) versus low
(NG2low) levels of NG2 expression and the outcome in these
subgroups evaluated in terms of risk-of-relapse. The cutoff of 40%
NG2 expression was associated with the highest hazard ratio (HR)
Table 1. Clinico-biological features of patients included in this study


















01 ND F MLL-AF4 NA 185 Neg 38 CR Neg Neg ND
02 7 M MLL-AF4 WT 300 Pos 56 Exitus Pos Neg Pos
03 10 M MLL-AF10 WT 21 Neg 45 CR Pos Pos Pos
04 6 F MLL-EPS15 WT 96 Neg 47 CR Pos Pos ND
05 6 F MLL-AF4 NA 515 Neg 84 Exitus Pos Neg ND
06 1.4 F MLL-AF4 WT 1332 Pos 59 Exitus Pos Pos Pos
07 6.5 M MLL-AF4 WT 204 Pos 48 Exitus Pos Neg Pos
08 3.5 M MLL-AF4 Mut 349 Pos 68 Exitus Pos Pos Pos
09 2 F MLL-AF4 Wt 263 Pos 42 CR Pos Pos Pos
10 3 F MLL-AF4 Mut 499 Pos 54 CR Pos Neg ND
11 2 F MLL-AF4 Mut 57 NA 37 CR Neg Neg ND
12 6.5 F MLL-AF4 Mut 337 Pos 33 Exitus Pos Pos ND




351 64% 51 6 CR 6
Exitus
83% 50% 100%
Abbreviations: CR, complete remission; F, female; M, male; MLL, mixed-lineage leukemia; Mut, mutated; NA, non-available; ND, not done; Neg, negative; Pos,
positive; WT, wild type/germline.
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of relapse, that is, 1.75, suggesting that patients with NG2
expression ⩾ 40% (NG2high) had a 75% increase in the hazard-of-
relapse as compared with patients with NG2 expression o40%
(NG2low) and was thus chosen as the cutoff for NG2 subgroup
deﬁnition in further analyses (Figure 1a). Accordingly, NG2high
infants showed a biologically/clinically relevant but no statistically
signiﬁcant trend toward a more aggressive phenotype (31%± 9
versus 50%± 10 5-year EFS ± s.e., P= 0.1, Figure 1b) than NG2low
patients that was associated with a more immature (CD10− or
byphenotypic) phenotype (82% versus 68%, P= 0.2, Figure 1c, left
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panel), higher WBC (85% versus 55% of patients with 4100× 109
WBC/l, P= 0.01, middle panel) and more common CNS disease
(80% versus 50% of patients with CNS disease, P= 0.1, right panel).
NG2 is a malleable marker that does not enrich for L-IC in iMLLr-
B-ALL
Increasing evidence based on maturation-dependent antigens,
including CD34, CD10 and CD20, suggests that there is no stem
cell hierarchy in pediatric B-ALL.8,9,11 NG2 is speciﬁcally expressed
in MLLr leukemia but its function remains enigmatic.14,15 Here we
addressed whether NG2 expression deﬁnes a blast population
enriched in L-IC activity. The ability of highly puriﬁed (FACS purity
498%, Figure 2a) NG2+ and NG2− blasts to initiate leukemia was
interrogated by IBM transplantation into NSG mice (n= 243)
following a limiting dilution (200k–1k blasts) transplantation
approach summarized in Figure 2b. The majority (83%) of iMLLr
samples were able to transfer the leukemia onto primografts
(Table 1, Supplementary Table S1). As expected, EFS decreased
with increasing doses of blasts transplanted (Figure 2c); however,
with the exception of a slightly (P= 0.06) more aggressive
behavior of NG2− blasts transplanted at very high dose (200k),
no differences were observed in either EFS or frequency of
engrafted mice between NG2+ and NG2− populations injected at
decreasing cell doses (Figure 2c, Supplementary Table S1). The
estimated frequency of LIC was similar between NG2+ and NG2−
populations (Figure 2d). Importantly, both NG2+ and NG2−
engrafted leukemias remained MLLr and mirrored the original
pro-B phenotype (CD45+CD19+CD10−) (Figure 2e), with engrafted
mice presenting very similar BM and extramedullary hematopoie-
tic site inﬁltration (Figure 2f), splenomegaly, high WBC counts and
a skewed granulocytic-to-lymphoid cell representation in PB
(Figure 2g). Interestingly, NG2 expression was malleable as
determined by the ability of both NG2+ and NG2− populations
to re-establish in vivo the original leukemia immunophenotype
with a continuum expression of NG2 (Figures 2a and e).
For serial transplantation experiments, 200k or 10k leukemic
cells from primografts were transplanted into secondary mice,
rendering a lower EFS (higher aggressiveness, Figure 3a, Supple-
mentary Table S2) than that observed in primary recipients;
however, no differences in EFS were observed between mice
transplanted with NG2+ or NG2− primografts (Figure 3a), suggest-
ing an overall enrichment of L-ICs in secondary recipients
irrespective of NG2 expression. Importantly, secondary leukemias
from NG2+ and NG2− primografts retained a pro-B phenotype
(Supplementary Figure S1A), similar inﬁltration levels in BM and
extramedullary hematopoietic sites (Figure 3b), splenomegaly,
high WBC counts (Figure 3c) and skewed differentiation toward
the lymphoid compartment in PB (Supplementary Figure S1B). Of
note, the continuum NG2 expression was reproduced in
secondary mice (Supplementary Figure S1A), demonstrating the
malleability of NG2 expression.
Figure 2. Leukemia development and phenotype in primografts of NG2+ and NG2− blast populations. (a) Representative
NG2 immunophenotype of diagnostic MA4+ BM samples and high-purity FACS-sorting of NG2+ and NG2− populations. More than 95% of
NG2+ and NG2− blasts carry the t(4;11)/MA4 by ﬂuorescence in situ hybridization (FISH). (b) Outline of the in vivo experimental design. NG2+ or
NG2− blasts were IBM-transplanted into NSG mice at day 0. The health of the mice and leukemia development were monitored over 20 weeks.
Mice were killed when disease was evident, when leukemic cells were 10% in PB or at day 140 (in the absence of symptoms or PB
engraftment). (c) Kaplan–Meier survival curves for EFS according to decreasing cell doses (200k to 1k) for NG2+ and NG2− transplanted mice
(n= 245). (d) Estimated frequency (and 95% conﬁdence interval) of L-IC in NG2+ and NG2− primografts calculated for cell doses o200k or
o50k. (e) Representative ﬂow cytometric analysis of leukemic mice. The human graft, identiﬁed as CD45+HLA-ABC+, reproduces the pro-B
phenotype (CD34+CD19+CD10−) seen in patients. Engrafted leukemias always re-establish NG2 variable expression and carry the t(4;11)/MA4
as detected by dual-fusion or break-apart FISH. (f) Level of leukemia engraftment in hematopoietic tissues from mice transplanted with NG2+
and NG2− blasts. Each dot represents a transplanted mouse and bars represent mean level of engraftment. (g) Both NG2+ and NG2−
transplanted mice consistently displayed splenomegaly, high WBC counts and a skewed granulocytic-to-lymphoid cell representation in PB.
Control group includes non-engrafted mice. *Po0.05.
Figure 3. NG2 expression does not enrich for L-IC capacity in
secondary recipients. (a) Kaplan–Meier survival curves for EFS
according to different cell doses transplanted into secondary
recipients (n= 60). Black and gray lines represent secondary
recipients transplanted with NG2+ and NG2− primary animals,
respectively. Dotted line depicts EFS rate of 50%. (b) Percentage of
long-term leukemic engraftment in the injected (IT) and contral-
ateral (CL) tibia, liver, spleen and PB of secondary mice.
(c) Secondary recipients of cells from either NG2+ or NG2− primary
mice consistently displayed splenomegaly and high WBC counts.
*Po0.05.
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Figure 4. NG2 expression is upregulated in extramedullary hematopoietic tissues. (a) Percentage of NG2-expressing blasts (black bar) in
primary (top panels) and secondary (bottom panels) engrafted mice at killing (n= 245). The following tissues were analyzed: IT, intra-tibia; CL,
contralateral tibia; Liv, liver; Sp, spleen; PB, peripheral blood. Left panels, NG2+ mice. Right panels, NG2− mice. The initial condition represents
the percentage of NG2-expressing cells at the moment of transplantation: 100% for primary NG2+ mice (black bar) and 0% for primary NG2−
mice (gray bar). (b) RT-qPCR conﬁrming sevenfold higher expression of NG2 in xenografted liver as compared with BM. (c) NG2+ and NG2−
cells were sorted and IV injected. Mice were weekly monitored by FACS for chimerism and killed after 7–8 weeks. Leukemia engraftment in PB
is shown for NG2+ (black dots) and NG2− (gray dots) transplanted mice. (d) Threefold higher WBC counts in diagnostic NG2high versus NG2low
MLL-AF4+ infants. Mean of NG2+ cells was used as cutoff (Table 1). *Po0.05; NS, not signiﬁcant.
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NG2 is upregulated in extramedullary hematopoietic tissues in
iMLLr-B-ALL
Despite the IBM transplantation of a pure population of NG2+ or
NG2− blasts, all leukemic cells engrafting primary and secondary
mice showed a re-establishment of the NG2 phenotype, reprodu-
cing the continuum observed in the original leukemia (Figures 2e,
3a and 4a). However, NG2 expression followed a tissue-speciﬁc
pattern upon primary and secondary transplantation (Figure 4a).
Figure 5. For caption see next page.
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Whereas ~ 40% of engrafted blasts expressed NG2 in BM, ~ 65% of
blasts were NG2+ in extramedullary hematopoietic tissues
(P= 0.01,Figure 4a). This was conﬁrmed by qRT-PCR, showing
sevenfold higher NG2 expression in extramedullary sites than in
BM (Figure 4b). Because leukemia reconstitution requires proper
homing to and seeding in the BM followed by exit of proliferating
blasts to extramedullary organs, NG2+ and NG2− blasts were IV-
transplanted and engraftment was analyzed 8 weeks later. IV-
transplanted NG2+ blasts engrafted extramedullary tissues in
100% of mice (8% reconstitution levels) while NG2− blasts did so
only in 13% of recipients with ~ 0.6% reconstitution levels
(Figure 4c). Importantly, analysis of leukocytosis in PB of iMLLr-
B-ALL patients showed that NG2high iMLLr-B-ALL infants displayed
a striking threefold higher number of circulating blasts than
NG2low patients (P= 0.01, Figure 4d). Together, these data suggest
that NG2 is upregulated in response to systemic inﬁltration/
migration, which is suggestive of a homeostatic adaptation of
leukemic cells.
NG2 is not a prospective marker for CNS-IC but is upregulated in
almost all MLLr blasts entering the CNS
Three pieces of information led us to address whether NG2 is
involved in CNS inﬁltration by MLLr blasts: (i) MLLr blasts
upregulate NG2 expression in extramedullary hematopoietic sites,
(ii) CNS inﬁltration is common in iMLLr-B-ALL and up to 75% of
relapses occur within the CNS,43 and (iii) NG2 antigen has an
important role in the developing brain and is associated with
melanoma cell migration and metastasis.21,22 As previously
reported, leukemia inﬁltrates were consistently found in
meninges/leptomeningeal space but were rarely found within
brain parenchyma13 (Figure 5a). The presence of inﬁltrating
human B-lymphoid blasts observed by hematoxylin and eosin
staining was always conﬁrmed by histopathology for CD45 and
CD19 (Figure 5b). In all, 8/11 (73%) primary leukemias tested for
CNS-inﬁltrating potential reproduced the patient phenotype
(Supplementary Figure S2A). Interestingly, 2/8 (25%) patients
engrafting CNS in mice showed no CNS involvement throughout
disease evolution, indicating that CNS-engrafting capacity seems
more prevalent than suggested by diagnostic cerebral-spinal ﬂuid
cytospins. Although the frequency of mice displaying CNS disease
was identical (50%) between NG2+- and NG2−-transplanted
groups (Supplementary Figure S2B, bottom panel), almost all
human blasts reaching the CNS were consistently NG2+,
irrespective of the NG2 phenotype of the population transplanted
(Figure 5c). In line with this result, NG2 expression was 55-fold
higher in CNS (spinal cord) than in BM (Figure 5d). These data
indicate that, while NG2 is not a marker to prospectively identify
CNS-inﬁltrating ability, it is highly upregulated in MLLr blasts
seeding the CNS.
To further conﬁrm NG2 with the migratory phenotype, we next
performed functional in vivo studies where NG2 antigen was
speciﬁcally blocked prior to IV xenotransplantation using either
the enzyme chase or two different clones of anti-NG2 MoAb (7.1
and 9.2.21). Blockage of NG2 with either compound resulted in a
pronounced loss of engraftment by NG2+ blasts 8 weeks after
transplantation (Figure 6). NG2+ blasts engrafted PB of all mice
(13%±6% reconstitution levels). whereas NG2-blocked blasts only
engrafted 50% of mice with extremely low reconstitution levels
(~1%, Figure 6, left panel). Recovered blasts were mainly NG2−
(Figure 6, right panel), conﬁrming a direct role of NG2 in
invasiveness of MLLr leukemia.
Global GEP reveals a migratory signature of NG2+ MLLr blasts
To identify patterns of gene expression that might provide a
molecular explanation for the biology of NG2 expression in MLLr,
we performed whole-genome GEP on FACS-puriﬁed NG2+ and
NG2− primary cells from t(4;11)/MA4+ pro-B ALL infants. A
heatmap representation of hierarchical clustering of genes
differentially expressed (20% upregulated or downregulated;
Po0.05) between NG2+ and NG2− primary blasts is represented
in Figure 7a. A total of only 281 genes (4%) were differentially
expressed between NG2+ and NG2− primary t(4;11)+ blasts. Of
these, 142 (50.5%) were upregulated and 139 (49.5%) down-
regulated in NG2+ cells, indicating little transcriptomic differences
between both cell subsets. To get insight into the biological
functions affected by differentially expressed genes, we used the
IPA software44–46 to compare NG2+ and NG2− primary t(4;11)+
blasts. We found that 8/12 (67%) signiﬁcant biological processes
predicted to be activated in the NG2+ blasts were associated with
‘leukemic cell migration/movement’ (Figure 7b), which is compa-
tible with the functional upregulation of NG2 observed in MLLr
blasts inﬁltrating extramedullary tissues and CNS.
To functionally support and validate patient GEP data, we
performed qPCR to quantify the expression of a panel of genes
associated with epithelial-to-mesenchymal transition/migration in
NG2+ and NG2− blasts harvested from primografts. Differentially
expressed genes were analyzed by IPA, and we found that the
majority (33/41, 81%) of the signiﬁcant biological processes were
associated with ‘cell migration/movement’ and were predicted to
be activated (z-score 42) in NG2+ circulating blasts (Figure 7c),
further conﬁrming a migratory signature observed in NG2+ MLLr
blasts inﬁltrating extramedullary hematopoietic tissues and CNS.
Figure 5. NG2 is not a prospective marker for CNS-IC but it is expressed in almost all MLLr blasts entering the CNS. (a) Representative H&E
staining of mice brains deﬁning xenografts with negative and positive CNS involvement (n= 60). S, skull. P, brain parenchyma. Leukemic
inﬁltration is exclusively found in leptomeninges and is marked by a white arrowhead. The right panel (macro) depicts the area magniﬁed on
each row. (b) H&E staining and immunohistochemistry for CD19 and CD45 performed on parafﬁn-embedded skulls from mice transplanted
with NG2+ and NG2− blasts (n= 60). Chimeric spleens and skulls from non-engrafted mice were used as positive and negative controls,
respectively. CD45+CD19+ human blasts are marked with a white arrowhead. (c) Immunoﬂuorescence staining for NG2, endomucin
(endothelial vessel marker) and DAPI on chimeric spleen, NG2+ and NG2− transplanted mice skull and control skull (non-engrafted mice). Dot
lines delimit areas with high density of cells and low density of NG2 marker in the chimeric spleen. Almost a 100% of human blasts in the CNS
are consistently NG2+, regardless of the NG2 phenotype of the population transplanted. (d) RT-qPCR showing 55-fold higher expression of
NG2 in the spinal cord than in BM. *Po0.05.
Figure 6. Speciﬁc blockage of NG2 antigen with either chase or
distinct clones of anti-NG2 MoAb results in dramatic loss of leukemia
engraftment (left panel, n= 29 mice from 2 independent patients).
Recovered blasts were mainly negative for NG2 (right panel).
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Figure 7. Global GEP reveals a migratory signature of NG2+ MLLr blasts. (a) Heatmap representation of hierarchical clustering of genes
differentially expressed between NG2+ and NG2− primary t(4;11)+ blasts (n= 3 independent leukemias). (b) Statistically signiﬁcant biological
functions identiﬁed using IPA on genes differentially expressed in NG2+ versus NG2− blasts. They are ranked by z-score. A z-score42 indicates
a predicted activation of that biological function. Biological functions associated with ‘leukemic cell viability and migration/movement’ are
shown in black. (c) Biological functions identiﬁed using IPA on genes differentially upregulated in NG2+ as compared with NG2− circulating
(PB/spleen) blasts in xenografted mice. The RT2 proﬁler PCR array speciﬁc for epithelial-to-mesenchymal transition/migration genes was used.
Biological functions associated with ‘migration/movement’ are shown in black.
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DISCUSSION
MLLr is associated with poor outcome in acute myeloid leukemia
and B-ALL.4,47 A clinico-biologically intriguing MLLr is MA4, which
results from the t(4;11)(q21;q23), and is the hallmark genetic
abnormality of infant t(4;11)+ pro-B/mixed B-ALL. Infant MA4+
B-ALL has a dismal prognosis associated with therapy refractori-
ness and CNS disease/relapse.6,48 Unfortunately, current disease
models fail to faithfully recapitulate the disease phenotype,
challenging in vivo studies aimed at understanding the disease
pathogenesis.4 Indeed, the nature of the target cell for transfor-
mation, the L-IC and the CNS-IC in iMLLr-B-ALL remans unkonwn.
Here we analyzed whether NG2 segregates L-ICs and/or CNS-ICs in
iMLLr-B-ALL (mainly MA4+ infants). NG2 is not expressed in normal
hematopoietic cells but it is speciﬁcally expressed in 11q23/MLLr
leukemias, reason for which it is currently used in immunophe-
notyping panels for its predictive value in leukemia diagnosis and
minimal residual disease studies.16–20
Longstanding evidence justiﬁes the biological interest in NG2 as
a potential surface marker involved in leukemia propagation and
CNS involvement.14,15 We have previously demonstrated that NG2
expression may be dependent on the cell of origin where a
speciﬁc leukemic abnormality occurs.14 For instance, NG2 might
be speciﬁcally regulated when leukemic drivers arise either in a
speciﬁc lineage-committed progenitor or in a more immature
hematopoietic stem cells. Furthermore, iMLLr-B-ALL patients
commonly show CNS disease either at presentation or at
relapse,43 NG2 has a role in the developing brain and is associated
with melanoma cell migration/metastasis.21,22 Our functional data
following a limiting dilution approach in NSG mice serially
transplanted with highly puriﬁed NG2+ or NG2− MA4+ blasts
conﬁrms the high-risk evolution of MA4+ iB-ALL since as many as
83% and 100% of patient samples are able to transfer the
leukemia onto primografts and secondary recipients, respectively,
despite transplanting a limited number of cells. Interestingly,
however, while NG2 does not enrich for L-IC or CNS-IC in iMLLr-B-
ALL, its expression is malleable as determined by the ability of
both NG2+ and NG2− cell fractions to re-establish in vivo the
original leukemia immunophenotype with a continuum of NG2
expression. This data, together with previous work from several
laboratories using other maturation-dependent antigens, includ-
ing CD34, CD10 and CD20, support the notion that high-risk MLLr-
B-ALL does not follow a stem cell hierarchy in pediatric/infant B-
ALL.8,9,11 Recent ﬁndings from Vormoor laboratory support our
data as they found that NG2 was not expressed in MLLr CD34+
CD38− hematopoietic stem cells but was upregulated in
differentiated CD33+ and CD19+ MLLr acute myeloid leukemia
and ALL blasts.49,50
Our study sheds light on the mechanisms of CNS disease/
relapse commonly seen in iMLLr-B-ALL. First, NG2 expression does
not allow for prospective identiﬁcation of the CNS-IC in iMLLr-B-
ALL, as there is no selective trafﬁcking of NG2+ or NG2− cell
fractions into the CNS. Second, our data in iMLLr-B-ALL match
recent elegant studies by Williams et al.13 showing that CNS-
inﬁltrating capacity is a generic property of B-ALL blasts. Third, as
demonstrated for MLL germline pediatric B-ALL, iMLLr-B-ALL is
almost exclusively found in the meninges/leptomeningeal space
and rarely in the brain parenchyma, suggesting that B-ALL blasts
cross the cerebrospinal ﬂuid barrier rather than the blood–brain
barrier. Fourth, our xenograft model recapitulated well CNS
disease in iMLLr-B-ALL as CNS engraftment matched in the
majority of primary patient xenograft pairs, even when only 1000
primary cells were transplanted. Importantly, CNS engraftment in
mice was seen in 8/11 (73%) diagnostic samples; 6/7 (86%) from
infants with overt CNS disease and 2/4 (50%) from patients
diagnosed to be CNS negative by diagnostic lumbar puncture. In
agreement with Williams et al.,13 we propose that current
cytological examination may misdiagnose CNS-negative patients,
as many of these have B-ALL blasts capable to colonize and graft
the CNS. These ﬁndings support that all the children/infants
should beneﬁt from prophylactic intrathecal CNS-targeted
therapy.
A major contribution of this work is the ﬁnding that, while NG2
does not enrich for L-IC or CNS-IC, it constitutes a malleable
marker highly upregulated in blasts inﬁltrating extramedullar
hematopoietic sites and CNS in iMLLr-B-ALL. Loss-of-function
experiments for NG2 provided a deﬁnitive conﬁrmation of its role
in migration and engraftment ability of MLLr B-ALL blasts. Our
in vivo data were supported by GEP studies, revealing a migratory
molecular signature observed in NG2+ MLLr blasts inﬁltrating
extramedullary hematopoietic tissues and CNS. Clinical data from
infants enrolled in the Interfant treatment protocol revealed that
NG2high iMLLr-B-ALL patients presented threefold higher number
of circulating blasts, suggesting that NG2 is upregulated in
response to systemic inﬁltration/migration, suggestive of a
homeostatic adaptation of leukemic cells. Interestingly, we
previously reported that RAS mutations cooperate with MA4 to
promote extramedullary engraftment and migration of cord blood
CD34+ hematopoietic stem and progenitor cells36; however, here
we found no link/correlation between RAS mutations and CNS
inﬁltration. Further genetic and live imaging studies will be
necessary to unveil whether NG2 antigen is regulated before BM
exit to facilitate migration or, conversely, is regulated in
extramedullary tissues/CNS as an immunological surveillance-
evading strategy and adaption to foreign splenic/CNS
microenvironment.
Clinical data reveals that NG2high iMLLr-B-ALL patients display a
trend toward a more immature/aggressive phenotype associated
with lower EFS, higher number of circulating blasts and higher
CNS relapse. This not only supports the prophylactic use of
intrathecal CNS-targeted therapy in all children but should also
encourage further studies to address whether targeting NG2 offers
a therapeutic window to reduce the risk of CNS disease and/or
provide safer CNS-directed therapies. Because NG2 is speciﬁcally
upregulated in extramedullary hematopoietic sites and CNS but is
not enriched in either L-ICs or CNS-IC, these novel therapies
should concentrate on effective eradication of NG2+ cells that
have managed to evade immunological surveillance and have
adapted to new microenvironments in extramedullary sites and
CNS, rather than targeting selective trafﬁcking or entry
mechanisms.
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